دورية أكاديمية
3MO Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2
| العنوان: | 3MO Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2 |
|---|---|
| المؤلفون: | Gentzler, R.D., Spira, A., Melosky, B., Owen, S., Burns, T., Massarelli, E., Nagasaka, M., Fang, B., Sanborn, R.E., Rodriguez, O.G. Arrieta, Card, C., Cappuzzo, F., Xia, K., Chu, P-L., Shah, S., Diorio, B., Garvin, A., Mahadevia, P., Bauml, J.M., Reckamp, K. |
| المساهمون: | Johnson & Johnson Innovative Medicine |
| المصدر: | ESMO Open ; volume 9, page 102582 ; ISSN 2059-7029 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2024 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| مصطلحات موضوعية: | Cancer Research, Oncology |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.esmoop.2024.102582 |
| الإتاحة: | https://doi.org/10.1016/j.esmoop.2024.102582Test https://api.elsevier.com/content/article/PII:S2059702924003508?httpAccept=text/xmlTest https://api.elsevier.com/content/article/PII:S2059702924003508?httpAccept=text/plainTest |
| حقوق: | https://www.elsevier.com/tdm/userlicense/1.0Test/ ; http://creativecommons.org/licenses/by-nc-nd/4.0Test/ |
| رقم الانضمام: | edsbas.7B3B0BBD |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.esmoop.2024.102582 |
|---|